ARTICLE | Financial News
Xenikos raises $30M series B for GVHD
May 18, 2018 2:32 AM UTC
Xenikos B.V. (Nijmegen, the Netherlands) raised $30 million in a tranched series B round co-led by new investors Medicxi and RA Capital.
In early 2019, the company plans to start Phase III testing in the U.S. and EU of lead candidate T-Guard to treat steroid-resistant, acute graft-versus-host disease (GvHD)...
BCIQ Company Profiles
BCIQ Target Profiles